新辅助和辅助治疗肾癌的前景。

The Promise of Neoadjuvant and Adjuvant Therapies for Renal Cancer.

机构信息

Department of Urology, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Annex 1-L04-Uro, Singapore 308433, Singapore.

Division of Urologic Oncology, The Ohio State University Comprehensive Cancer Center, 915 Olentangy River Road, Suite 3100, Columbus, OH 43212, USA.

出版信息

Urol Clin North Am. 2023 May;50(2):285-303. doi: 10.1016/j.ucl.2023.01.011.

DOI:10.1016/j.ucl.2023.01.011

PMID:36948672

Abstract

Because metachronous metastatic disease will develop in 20% to 40% of patients with presumed localized renal cell carcinoma (RCC) treated surgically, research is focused on neoadjuvant and adjuvant systemic therapy, to improve disease-free and overall survival. Neoadjuvant therapies trialed include anti-vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) agents, or combination therapies (immunotherapy with TKI), and aim to improve resectability of locoregional RCC. Adjuvant therapies trialed include cytokines, anti-VEGF TKI agents, or immunotherapy. These therapeutics can facilitate the surgical extirpation of the primary kidney tumor in the neoadjuvant setting and improve disease-free survival in the adjuvant setting.

摘要

由于预计接受手术治疗的局限性肾细胞癌 (RCC) 患者中有 20%至 40%会出现异时性转移疾病，因此研究的重点是新辅助和辅助全身治疗，以改善无病生存率和总生存率。新辅助治疗试验包括抗血管内皮生长因子 (VEGF) 酪氨酸激酶抑制剂 (TKI) 药物或联合治疗（TKI 联合免疫治疗），旨在提高局部 RCC 的可切除性。辅助治疗试验包括细胞因子、抗 VEGF TKI 药物或免疫治疗。这些疗法可以在新辅助治疗中促进原发性肾肿瘤的手术切除，并在辅助治疗中改善无病生存率。